Pretomanid is becoming tested as Element of a mix regimen such as moxifloxacin and PZA to the treatment of equally drug-inclined and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, authorised from the US FDA for treatment of multidrug-resistant tuberculosis in 2012, is also staying investigated in drug-vulnera